insulin

[SymbioCellTech (GlobeNewswire, Inc.)] SymbioCellTech announced the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human Neo-Islet™ in a third, clinically relevant model of human Type 1 Diabetes.

[Scientific Reports] Investigators elucidated whether regulation of growth hormone secretagogue receptor-1a (GHS-R1a), one of the ghrelin receptors, improved the therapeutic effects of islet transplantation using [D-Lys3]-GHRP-6, a specific GHS-R1a antagonist.

[Cell Death Discovery] Researchers determined the clinical value, biological functions, and potential mechanisms of RNA-binding motif protein 15 (RBM15) in hepatocellular carcinoma.

[Stem Cell Reviews and Reports] DPP4 activity may modulate different aspects of MSC regenerative capacity. The authors analyze the effect of different DPP4 substrates on MSC and discuss how the regulation of DPP4 activity by DPP4 inhibitor can be applied in regenerative medicine.

[vTv Therapeutics, Inc.] vTv Therapeutics Inc. announced positive results of a mechanistic study of TTP399 in patients with type 1 diabetes. The study demonstrated that patients with T1D taking TTP399 experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis.

[Cellular Reprogramming] MSCs were extracted from adipose, umbilical cord, and placental tissues. The expression levels of 80 cytokines were detected, and the data demonstrated that the three MSC types abundantly secreted insulin-like growth factor-binding protein (IGFBP)-4, IGFBP-3, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, IGFBP-6, monocyte chemoattractant protein-1, and granulocyte colony-stimulating factor.